| William Hood Arledge Jr, PHARMACIST | |
|
10 Medical Park Pharmacy, Columbia, SC 29203 | |
| (803) 434-4686 | |
| Not Available |
| Full Name | William Hood Arledge Jr |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 10 Medical Park Pharmacy, Columbia, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194922633 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 4765 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| William Hood Arledge Jr, PHARMACIST 677 Townes Rd, Columbia, SC 29210-3755 Ph: (803) 798-4015 | William Hood Arledge Jr, PHARMACIST 10 Medical Park Pharmacy, Columbia, SC 29203 Ph: (803) 434-4686 |
News Archive
Botulinum neurotoxin type A (BoNT/A)—better known as Botox—reduces responses to an inflammation-related pain stimulus when injected into the spinal canal in mice, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Thomas A. Moore, chairman and CEO of Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has issued the following statement to shareholders regarding the recent transition to the OTCQB from the OTCBB:
An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.
In a study that included 3.3 million percutaneous coronary intervention procedures, major bleeding after PCI was associated with significantly increased in-hospital mortality, with an estimated 12 percent of deaths after PCI related to bleeding complications, according to a study appearing in the March 13 issue of JAMA.
Trevena, Inc., the leader in discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today the initiation of a Phase I clinical trial of TRV130, a novel candidate designed for the intravenous treatment of moderate-to-severe post-operative pain.
› Verified 3 days ago
Dr. Dargan Elizabeth Mayer, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 818 Harden St, Columbia, SC 29205 Phone: 803-799-0043 | |
Dr. Brittney Brooks Mcniece, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 163 Sandhurst Rd, Columbia, SC 29210 Phone: 706-767-1170 | |
Mrs. Janna Hollis, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1326 Bush River Rd, Columbia, SC 29210 Phone: 803-750-3284 Fax: 803-750-3280 | |
Alexander Corboy, DR. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6439 Garners Ferry Rd, Columbia, SC 29209 Phone: 803-776-4000 | |
Alfred Jones, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 507 Piney Grove Rd, Columbia, SC 29210 Phone: 803-875-7140 | |
Dr. Hayley Tatro, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6439 Garners Ferry Rd, Columbia, SC 29209 Phone: 803-776-4000 | |
Dr. William Chad Hancock, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6169 Saint Andrews Rd, Columbia, SC 29212 Phone: 803-798-5957 Fax: 803-798-8837 |